Log In
BCIQ
Print this Print this
 

Rilutek, riluzole

  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionGlutamate antagonist
Molecular Target Metabotropic glutamate receptor subtype 5 (mGluR5) (GRM5)
Mechanism of ActionMetabotropic glutamate receptor subtype 5 (mGluR5) modulator
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationAmyotrophic lateral sclerosis (ALS)
Indication DetailsTreat amyotrophic lateral sclerosis (ALS); Treat amyotrophic lateral sclerosis (ALS) of both bulbar and limb onset
Regulatory Designation
PartnerCovis Pharma S.a.r.l.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/15/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today